Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
 - EconoTimes)
NEW YORK, May 15, 2017 -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Intra-Cellular Therapies, Inc. (“Intra-Cellular” or the “Company”) (NASDAQ symbol:ITCI) in United States District Court on behalf of a class consisting of investors who purchased or otherwise acquired Intra-Cellular securities between August 12, 2014 and April 28, 2017, inclusive (the “Class Period”), seeking to recover compensable damages caused by Defendants’ violations of the Securities Exchange Act of 1934.
The Complaint alleges that, throughout the Class Period, Intra-Cellular made false and/or misleading statements and/or failed to disclose: that findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; that these findings posed an additional safety concern regarding lumateperone; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.
On August 4, 2016, Intra-Cellular’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” On May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients. When this information was released, Intra-Cellular’s stock price lowered materially, which harmed investors according to the Complaint.
If you wish to serve as lead plaintiff, you must move the Court no later than July 11, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.
